Brain tumor targeting of magnetic nanoparticles for potential drug delivery: Effect of administration route and magnetic field topography

被引:116
作者
Chertok, Beata [1 ]
David, Allan E. [1 ,2 ]
Yang, Victor C. [1 ,3 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] ISTN Inc, York, PA 17404 USA
[3] Tianjin Med Univ, Tianjin Key Lab Technol Enabling Dev Clin Therape, Sch Pharm, Tianjin 300070, Peoples R China
关键词
Iron oxide nanoparticles; Magnetic targeting; Brain tumor targeting; Intra-carotid administration; Magnetic field topography; INTRAARTERIAL; BIODISTRIBUTION; CHEMOTHERAPY; FLOW;
D O I
10.1016/j.jconrel.2011.06.033
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Our previous studies demonstrated feasibility of magnetically-mediated retention of iron oxide nanoparticles in brain tumors after intravascular administration. The purpose of this study was to elucidate strategies for further improvement of this promising approach. In particular, we explored administration of the nanoparticles via a non-occluded carotid artery as a way to increase the passive exposure of tumor vasculature to nanoparticles for subsequent magnetic entrapment. However, aggregation of nanoparticles in the afferent vasculature interfered with tumor targeting. The magnetic setup employed in our experiments was found to generate a relatively uniform magnetic flux density over a broad range, exposing the region of the afferent vasculature to high magnetic force. To overcome this problem, the magnetic setup was modified with a 9-mm diameter cylindrical NdFeB magnet to exhibit steeper magnetic field topography. Six-fold reduction of the magnetic force at the injection site, achieved with this modification, alleviated the aggregation problem under the conditions of intact carotid blood flow. Using this setup, carotid administration was found to present 1.8-fold increase in nanoparticle accumulation in glioma compared to the intravenous route at 350 mT. This increase was found to be in reasonable agreement with the theoretically estimated 1.9-fold advantage of carotid administration, R-d. The developed approach is expected to present an even greater advantage when applied to drug-loaded nanoparticles exhibiting higher values of R-d. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:393 / 399
页数:7
相关论文
共 28 条
[1]
Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[2]
Alexiou C, 2000, CANCER RES, V60, P6641
[3]
Barratt, 2000, Pharm Sci Technol Today, V3, P163
[4]
Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model [J].
Brigger, I ;
Morizet, J ;
Laudani, L ;
Aubert, G ;
Appel, M ;
Velasco, V ;
Terrier-Lacombe, MJ ;
Desmaële, D ;
d'Angelo, J ;
Couvreur, P ;
Vassal, G .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :29-40
[5]
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors [J].
Chertok, Beata ;
Moffat, Bradford A. ;
David, Allan E. ;
Yu, Faquan ;
Bergemann, Christian ;
Ross, Brian D. ;
Yang, Victor C. .
BIOMATERIALS, 2008, 29 (04) :487-496
[6]
Comparison of Electron Spin Resonance Spectroscopy and Inductively-Coupled Plasma Optical Emission Spectroscopy for Biodistribution Analysis of Iron-Oxide Nanoparticles [J].
Chertok, Beata ;
Cole, Adam J. ;
David, Allan E. ;
Yang, Victor C. .
MOLECULAR PHARMACEUTICS, 2010, 7 (02) :375-385
[7]
Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking [J].
Chertok, Beata ;
David, Allan E. ;
Moffat, Bradford A. ;
Yang, Victor C. .
BIOMATERIALS, 2009, 30 (35) :6780-6787
[8]
CHIRAS J, 1988, J NEURORADIOLOGY, V15, P31
[9]
Cancer theranostics: the rise of targeted magnetic nanoparticles [J].
Cole, Adam J. ;
Yang, Victor C. ;
David, Allan E. .
TRENDS IN BIOTECHNOLOGY, 2011, 29 (07) :323-332
[10]
PHARMACOLOGIC RATIONALE FOR REGIONAL DRUG DELIVERY [J].
COLLINS, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (05) :498-504